Services-Commercial Physical & Biological Research · SIC 8731
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
CRL
Latest revenue
$995.8M
as of 2026-03-28
Latest net income
$-14.8M
as of 2026-03-28
Net margin
-1.5%
as of 2026-03-28
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $7.72B
- Enterprise value
- $9.70B
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- 2.27×
- Dividend yield
- 0.0%
- 52-wk high
- $228.88
- 52-wk low
- $132.58
- Beta
- —
- Shares out
- 48.2M
5-year trend
What this company does
Charles River Labs supplies pharmaceutical and biotech companies with the lab animals, preclinical safety testing, and manufacturing-support services needed to develop new drugs before human trials. The Discovery and Safety Assessment segment generates the bulk of revenue by running regulated toxicology and discovery studies for drug developers. Following a board strategic review, the company is restructuring aggressively, divesting roughly 7% of revenue, and pivoting toward non-animal testing methods as biotech client demand softens and DSA backlog slips to $1.8 billion.
Generated from CRL's filing dated 2026-02-18
Key risks
- DSA backlog fell to $1.8B from $2.0B as biopharma clients cut spending, pressuring Charles River's largest segment amid cautious budgets.
- Ongoing SEC enforcement investigation into non-human primate sourcing and disclosures since May 2023; potential fines, penalties unquantified.
- FDA's April 2025 push to replace animal testing with non-animal methods threatens core research-models franchise; ~7% of 2025 revenue being divested.
Generated from CRL's filing dated 2026-02-18
Profitability
Operating margin
0.6%
88.8%Net margin
-3.6%
755.7%Return on equity
-4.6%
811.1%Return on assets
-2.0%
785.9%Leverage
Debt / equity
1.25×
6.8%Long-term debt / equity
0.68×
4.3%Debt / assets
55.6%
3.0%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-28 | $995.8M | +1.2% | $-14.8M | -158.3% | -1.5% |
Q4 2025 2025-12-27 | $994.2M | -0.8% | $-276.6M | -28.9% | -27.8% |
Q3 2025 2025-09-27 | $1.00B | -0.5% | $54.4M | -21.9% | 5.4% |
Q2 2025 2025-06-28 | $1.03B | +0.6% | $52.3M | -44.4% | 5.1% |
Q1 2025 2025-03-29 | $984.2M | -2.7% | $25.5M | -65.1% | 2.6% |
Q4 2024 2024-12-28 | $1.00B | — | $-214.5M | — | -21.4% |
Q3 2024 2024-09-28 | $1.01B | -1.6% | $69.7M | -20.3% | 6.9% |
Q2 2024 2024-06-29 | $1.03B | -3.2% | $94.1M | -3.0% | 9.2% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Services-Commercial Physical & Biological Research · SIC 8731
Your notes
Keep private notes on CRL — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$4.4K
Insider selling
$251.6K
Net activity
−$247.2K
Distinct insiders
1
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns CRL
Institutional value
$4.36B
Total shares held
26.8M
Distinct holders
381
As of
2026-03-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 3.9M | $665.7M | — | New |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 3.2M | $552.4M | — | New |
| 3 | Invesco Ltd. | 2.4M | $413.5M | — | New |
| 4 | VANGUARD PORTFOLIO MANAGEMENT LLC | 2.3M | $395.8M | — | New |
| 5 | Allspring Global Investments Holdings, LLC | 2.0M | $348.6M | — | New |
| 6 | DIMENSIONAL FUND ADVISORS LP | 1.7M | $285.0M | — | New |
| 7 | COOKE & BIELER LP | 867.9K | $149.7M | — | New |
| 8 | SEI INVESTMENTS CO | 757.1K | $130.6M | — | New |
| 9 | UBS Group AG | 731.5K | $126.2M | — | New |
| 10 | Clearbridge Investments, LLC | 632.6K | $109.1M | — | New |
| 11 | MACKENZIE FINANCIAL CORP | 594.8K | $102.6M | — | New |
| 12 | BANK OF MONTREAL /CAN/ | 445.9K | $76.9M | — | New |
| 13 | Bank of New York Mellon Corp | 295.9K | $51.0M | — | New |
| 14 | Boston Trust Walden Corp | 285.4K | $49.2M | — | New |
| 15 | VANGUARD FIDUCIARY TRUST CO | 277.0K | $47.8M | — | New |
| 16 | DEUTSCHE BANK AG\ | 275.4K | $47.5M | — | New |
| 17 | PRIMECAP MANAGEMENT CO/CA/ | 266.9K | $46.0M | — | New |
| 18 | BNP PARIBAS FINANCIAL MARKETS | 252.2K | $43.5M | — | New |
| 19 | JPMORGAN CHASE & CO | 264.4K | $42.2M | — | New |
| 20 | UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 218.9K | $37.8M | — | New |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
- 1
DSA backlog fell from $2.0B to $1.8B; when does book-to-bill inflect, and are you seeing further pricing pressure from biotech clients?
- 2
The FDA's NAMs pilot directly threatens in vivo safety testing—what percentage of DSA revenue is at risk, and over what timeframe?
- 3
You're divesting 7% of 2025 revenue as 'underperforming'—which segments, what margin drag are you removing, and expected proceeds?
Refreshed when CRL files a new report · last from 2026-02-18